William Blair Brokers Reduce Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at William Blair lowered their Q4 2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Tuesday, November 26th. William Blair analyst M. Minter now anticipates that the company will post earnings of $0.10 per share for the quarter, down from their prior forecast of $0.18. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($4.75) per share.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The firm had revenue of $104.76 million during the quarter, compared to analysts' expectations of $98.71 million. During the same quarter in the previous year, the business earned ($1.32) earnings per share.

AXSM has been the subject of a number of other research reports. Royal Bank of Canada boosted their price objective on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an "outperform" rating in a research report on Friday, October 4th. Needham & Company LLC reissued a "buy" rating and set a $130.00 price target on shares of Axsome Therapeutics in a report on Tuesday, November 12th. UBS Group reduced their price target on Axsome Therapeutics from $107.00 to $105.00 and set a "buy" rating for the company in a research report on Tuesday, August 6th. StockNews.com raised Axsome Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $107.00 target price on shares of Axsome Therapeutics in a report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $124.93.

Axsome Therapeutics Stock Performance

AXSM stock traded up $2.62 during trading on Thursday, reaching $99.65. The stock had a trading volume of 487,421 shares, compared to its average volume of 619,294. The firm has a market cap of $4.83 billion, a PE ratio of -15.26 and a beta of 1.26. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The stock's 50 day moving average is $91.37 and its two-hundred day moving average is $85.57. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $105.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC grew its stake in Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company's stock worth $97,786,000 after buying an additional 185,951 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Axsome Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 908,459 shares of the company's stock valued at $81,659,000 after acquiring an additional 23,564 shares during the period. Wellington Management Group LLP grew its position in shares of Axsome Therapeutics by 1.1% during the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company's stock worth $66,750,000 after acquiring an additional 8,125 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Axsome Therapeutics by 1.4% in the 2nd quarter. Millennium Management LLC now owns 739,819 shares of the company's stock valued at $59,555,000 after acquiring an additional 10,401 shares during the period. Finally, Hood River Capital Management LLC raised its position in Axsome Therapeutics by 5.4% in the 2nd quarter. Hood River Capital Management LLC now owns 549,066 shares of the company's stock valued at $44,200,000 after purchasing an additional 28,316 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Axsome Therapeutics

In other news, Director Mark E. Saad sold 11,016 shares of the firm's stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total value of $1,005,870.96. Following the completion of the transaction, the director now owns 10,002 shares of the company's stock, valued at approximately $913,282.62. This trade represents a 52.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 22.40% of the stock is currently owned by company insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.